

DYNAVAX

Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 6, 2023 at 4:05 PM EDT

EMERYVILLE, Calif., Sept. 6, 2023 /PRNewswire/ -- [Dynavax Technologies Corporation](#) (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 12:00 p.m. ET.



The fireside chat will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at <https://investors.dynavax.com/events-presentations>.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on [LinkedIn](#) and [Twitter](#).

For Investors/Media:

Paul Cox

pcox@dynavax.com

510-665-0499

Nicole Arndt

namdt@dynavax.com

510-665-7264

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301919772.html>

SOURCE Dynavax Technologies